Thursday, August 21, 2014 Last update: 3:03 AM
FreshNews.com - All Company Technology News Since 1996

Ligand to Report First Quarter Results on May 7th

Companies mentioned in this article: Ligand Pharmaceuticals Incorporated

SAN DIEGO -- (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report first quarter 2014 financial results on May 7, 2014. Ligand’s President and CEO John Higgins, Executive Vice President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.

First Quarter Earnings Call
 
What:   Ligand Pharmaceuticals conference call to discuss financial results and provide general business update
 
When: Wednesday, May 7, 2014
 
Time: 6:00 a.m. Pacific time (9:00 a.m. Eastern time)
 
Webcast:

Conference call and replay accessible at www.ligand.com

 
Conference Call: (877) 407-4019 within the U.S.
(201) 689-8337 outside the U.S.
Passcode: Ligand
 
Replay: (877) 660-6853 within the U.S.
(201) 612-7415 outside the U.S.
Passcode: 13580713

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.


Copyright © Business Wire 2014
Contact:

Ligand Pharmaceuticals Incorporated
President and CEO
John Higgins, 858-550-7500
investors@ligand.com
@Ligand_LGND
or
LHA
Bruce Voss, 310-691-7100
bvoss@lhai.com
@LHA_IR_PR